Skip to main content

Table 1 Baseline characteristics with comparison between patients with pathological versus normal levels of NT-proBNP

From: The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study

  All patients NT-proBNP-negativea n = 202 NT-proBNP-positivea n = 35 P value
Age, years 51.9 (13.0) 51.4 (12.9) 54.3 (13.7) 0.17
Female gender 175 (73.5) 151 (74.8) 23 (65.7) 0.26
Disease duration, years 2.3 (1.2) 2.2 (1.1) 2.4 (1.3) 0.41
RF IgM-positive, ≥ 25 114 (47.9) 97 (48.0) 16 (45.7) 0.80
Anti-CCP-positive, ≥ 25 144 (60.5) 125 (61.9) 18 (51.4) 0.24
Sharp score 6.8 (11.8) 6.8 (12.3) 6.5 (8.1) 0.20
C-reactive protein, mg/L 9.9 (12.7) 9.2 (11.8) 13.9 (15.8) 0.05
DMARD user 124 (52.1) 104 (51.5) 19 (54.3) 0.76
NSAID user 109 (45.8 92 (45.5) 17 (48.6) 0.74
Glucocorticoid user, oral 65 (27.2) 51 (25.2) 14 (40) 0.07
  1. Values are presented as mean (standard deviation) for continuous variables and as number (percentage) for counts. aAge- and gender-adjusted reference levels. anti-CCP, anti-cyclic citrullinated peptide antibody; DMARD, disease-modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor; Sharp score, van der Heijde modified Sharp criteria.
\